This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses

This study has been completed.
Information provided by (Responsible Party):
Changi General Hospital Identifier:
First received: October 5, 2012
Last updated: October 9, 2012
Last verified: October 2012
Contrast enhanced EUS with the sonographic contrast agent DEFINITY™ has the potential to detect pancreatic cancer at an earlier stage, to improve current method of T staging and assessment of surgical resectability and also to distinguish between benign and malignant pancreatic masses. All these will translate into better clinical outcome, and also avoid unnecessary surgery in situations of unresectable cancers.

Pancreatic Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses

Resource links provided by NLM:

Further study details as provided by Changi General Hospital:

Enrollment: 33
Study Start Date: August 2009
Study Completion Date: October 2011

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A total of 50 subjects will be enrolled. The study population will be drawn from patients referred for EUS evaluation on basis of suspected pancreatic cancer. These patients could be either from clinics or from the hospital wards.

Inclusion Criteria:

  • Consecutive patients over a 1-year period referred for EUS examination due to suspected pancreatic lesions will be enrolled.
  • Age 21 years and above.
  • Ability to provide informed consent

Exclusion Criteria:

Patients with clinical conditions that preclude the use of DEFINITY™ will be excluded. These conditions are:

  • Right-to-left, bi-directional, or transient right-to-left cardiac shunts;
  • Worsening or clinically unstable congestive heart failure;
  • Acute myocardial infarction or acute coronary syndromes;
  • Serious ventricular arrhythmias or high risk for arrhythmias due to prolongation of the QT interval;
  • Respiratory failure;
  • Severe emphysema, pulmonary emboli or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature;
  • Hypersensitivity to DEFINITY™ or its components.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01703026

Changi General Hospital
Singapore, Singapore
Sponsors and Collaborators
Changi General Hospital
  More Information

Responsible Party: Changi General Hospital Identifier: NCT01703026     History of Changes
Other Study ID Numbers: CTC0900328
Study First Received: October 5, 2012
Last Updated: October 9, 2012

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases processed this record on August 18, 2017